GfK Healthcare's Roper Diabetes Patient Programme Launches Enhanced Annual Study For Western Europe: Six Focused Research Waves Across Five Countries
Gumbo
Study For Western Europe: Six Focused Research Waves Across Five Countries
Main Category: Diabetes
Article Date: 30 Aug 2009 - 0:00 PDT
GfK Healthcare's Roper Global Diabetes Programme, the definitive global
perspective on diabetes, announced today the launch of its enhanced
2009/2010 Western Europe Patient Study. Offering a holistic perspective of
the diabetes patient across five European countries, with robust insights
into patients' attitudes and behaviors towards treatments, testing and
lifestyles, the study now makes available to marketers greater reporting
frequency and focus across a variety of broad-based and niche diabetes
patient groups.
As the largest diabetes patient study of its kind - focused on delivering
direct-from-patient reporting of actual patient attitudes, behaviors and
treatment practices, rather than therapy-driven insights gleaned from
patient record research - the Roper Western Europe Diabetes Patient Study
covers France, Germany, Italy, Spain and the United Kingdom. The newly
enhanced offering for 2009/2010 provides a significant improvement over the
historical biennial reporting. Conducted as six separate monthly waves,
beginning in October 2009 and running through March 2010, each wave of the
study will focus on a different diabetes patient group, including Type 1
patients, Type 2 insulin users and users of new medications, to name a few.
The new Roper study retains its heritage, which for more than a decade has
delivered robust data, projected to represent the diabetes patient market,
the reliability of core Roper questions that have been tracked over time and
across countries and the ability for clients to add their own proprietary
questions. Here, the new multiwave format allows marketers to purchase and
add proprietary questions on a monthly basis, similar to an omnibus.
Deliverables include topline data at the end of each month, incorporating
optional charts and graphs. After the final wave, the collective data from
the six waves will be rolled up, weighted to be representative and projected
so that it is comparable to previous Roper studies for trending purposes. A
syndicated report will be issued by May 2010. Customization of reports and
presentations of the data will also be available.
"The changes we have made to the format and frequency of our long-standing
Roper study were the direct result of consultation with our Western European
clients," said Ian Pike, director of GfK Healthcare's Roper Global Diabetes
Group based in the United Kingdom. "Traditionally, our study mainly provided
strategic insights, but now, with the level of detail gleaned from the
separate waves covering each of the patient groups, the study provides more
utility and supports the ability for diabetes marketers to address tactical
issues among patients."
About the Roper Global Diabetes Programme
GfK Healthcare's Roper Global Diabetes Programme includes a series of
multiclient tracking studies with diabetes patients conducted annually in
the United States, Canada and Western Europe, as well as periodic studies in
Eastern Europe, Latin America and Asia Pacific. The 2009/2010 Roper Western
Europe Diabetes Patient Study provides key information on every facet of
diabetes, from patient attitudes and demographics to product usage, to
source of care and the doctor/patient relationship. The study, to be fielded
in six monthly waves across five European countries from October 2009
through March 2010, will be conducted via phone interviews with a sample of
1,500 diagnosed diabetes patients for the three random sample waves (months
1, 3, 5) and with a sample of 500 patients for each of the three niche
target group waves (months 2, 4, 6).
Source
GfK Healthcare
http://www.medicalnewstoday.com/articles/162255.php
Disclaimer: Any medical information published is not intended as a
substitute for informed medical advice and you should not take any action
before consulting with a health care professional. For more information,
please read our terms and conditions.